Please assess the completion status of the following clinical trial:

Trial Title: Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Acute Lymphoblastic Leukemia (ALL)~* BCR-ABL positive positive by PCR (central Lab)~* No previous treatment for ALL except for corticoids and cyclophosphamide less than 600 mg/m2~* Must be able to swallow tablets~* Lab results within normal limits (Potassium, Calcium, Magnesio, Phosphorus, Transaminases, Alkaline Phosphatase, Bilirrubine, Amylase, Lypase)~Exclusion Criteria:~* Heart disease~* Interval QTc Fridericia \> 480 msec~* Coumadin use~* Pregnancy~* PS = 4~* Previous medical history of etilism or/and pancreatic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- nilotinib (Type: EXPERIMENTAL): single arm study

Based on this trial design, predict the completion outcome and termination type (if applicable).